Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Pelabresib in Patients With Hematological or Solid Tumors
NCT06401356Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Aug 2024
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of pelabresib in hematologic malignancy, solid tumor, advanced cancer, sponsored by Novartis. Started Aug 2024; status: recruiting.
02
Drugs
pelabresib
03
Conditions
hematologic malignancysolid tumoradvanced cancer
Beyond the preview
Go deeper on NCT06401356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06401356.